Gonadorelin Side Effects: Safety Signals and Warnings
Gonadorelin safety concerns are compound-specific. The main listed side effects are Injection site reactions, Headache, and Nausea. The main warning signals are Ovarian hyperstimulation syndrome monitoring required during pulsatile therapy, Not for use in patients with pituitary tumors, and Anaphylaxis rare but reported.
Direct Answer
Gonadorelin has a well-established physiological and clinical evidence base, but its US approval is historical: Factrel and Lutrepulse are discontinued products. It remains a useful GnRH reference compound, while current availability and approved alternatives depend on jurisdiction and indication.
- Evidence grade
- Level A
- Research status
- Historical FDA Approval
- Category
- Sexual Health
- Evidence context
- HPA axis diagnostic testing, hypogonadotropic hypogonadism treatment, fertility protocol support, HPG axis research
Reported Side Effects
- Injection site reactions
- Headache
- Nausea
- Flushing
- Ovarian hyperstimulation syndrome (with pulsatile therapy in women)
- Multiple pregnancy risk
Warnings
- Ovarian hyperstimulation syndrome monitoring required during pulsatile therapy
- Not for use in patients with pituitary tumors
- Anaphylaxis rare but reported
- Continuous (non-pulsatile) administration will paradoxically suppress gonadotropins
Known or Plausible Interactions
- GnRH agonists/antagonists (interfere with diagnostic testing)
- Oral contraceptives (suppress pituitary response to testing)
- Dopamine agonists (may blunt GnRH response)
Regulatory Context
Gonadorelin products Factrel and Lutrepulse previously held FDA approval, but the listed US products are discontinued. Drugs@FDA does not identify the discontinuations as resulting from a safety or effectiveness finding. Gonadorelin therefore has historical, not currently marketed, US approval.
Evidence Snapshot
| Evidence grade | Level A |
|---|---|
| Research status | Historical FDA Approval |
| Best supported outcomes | Pituitary Function Assessment (Level A), Fertility Restoration (Level A), and LH/FSH Stimulation (Level A) |
| Primary citation count | 2 |
| Last reviewed | 2026-08-27 |
Quick Answers
What are the side effects of Gonadorelin?
Gonadorelin safety concerns are compound-specific. The main listed side effects are Injection site reactions, Headache, and Nausea. The main warning signals are Ovarian hyperstimulation syndrome monitoring required during pulsatile therapy, Not for use in patients with pituitary tumors, and Anaphylaxis rare but reported.
What is the evidence level for Gonadorelin?
Gonadorelin is rated Level A. Its current research status is Historical FDA Approval.
What is Gonadorelin best known for?
HPA axis diagnostic testing, hypogonadotropic hypogonadism treatment, fertility protocol support, HPG axis research.
Where can I read the full Gonadorelin evidence review?
The full evidence review is available at https://examinepeptides.com/library/gonadorelin.
Related Guides
How to Cite This Page
ExaminePeptides. "Gonadorelin Side Effects: Safety Signals and Warnings." Last reviewed 2026-08-27. https://examinepeptides.com/answers/gonadorelin-side-effects-safety/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.